Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
Fermé C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Diviné M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vié B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M; EORTC-GELA H8 Trial. Fermé C, et al. Among authors: lugtenburg pj. N Engl J Med. 2007 Nov 8;357(19):1916-27. doi: 10.1056/NEJMoa064601. N Engl J Med. 2007. PMID: 17989384 Free article. Clinical Trial.
Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
Neppelenbroek SIM, Geurts YM, Aleman BMP, Lugtenburg PJ, Rademakers SE, de Weijer RJ, Schippers MGA, Ta BDP, Plattel WJ, Zijlstra JM, van der Maazen RWM, Nijziel MR, Ong F, Schimmel EC, Posthuma EFM, Kersten MJ, Böhmer LH, Muller K, Koene HR, Te Boome LCJ, Bilgin YM, de Jongh E, Janus CPM, van Leeuwen FE, Schaapveld M. Neppelenbroek SIM, et al. Among authors: lugtenburg pj. J Clin Oncol. 2024 Jun 1;42(16):1903-1913. doi: 10.1200/JCO.23.01386. Epub 2024 Feb 15. J Clin Oncol. 2024. PMID: 38359378 Free PMC article.
Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.
Eertink JJ, Zwezerijnen GJC, Heymans MW, Pieplenbosch S, Wiegers SE, Dührsen U, Hüttmann A, Kurch L, Hanoun C, Lugtenburg PJ, Barrington SF, Mikhaeel NG, Ceriani L, Zucca E, Czibor S, Györke T, Chamuleau MED, Hoekstra OS, de Vet HCW, Boellaard R, Zijlstra JM. Eertink JJ, et al. Among authors: lugtenburg pj. Blood. 2023 Jun 22;141(25):3055-3064. doi: 10.1182/blood.2022018558. Blood. 2023. PMID: 37001036 Free PMC article.
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma.
Eertink JJ, Zwezerijnen GJC, Wiegers SE, Pieplenbosch S, Chamuleau MED, Lugtenburg PJ, de Jong D, Ylstra B, Mendeville M, Dührsen U, Hanoun C, Hüttmann A, Richter J, Klapper W, Jauw YWS, Hoekstra OS, de Vet HCW, Boellaard R, Zijlstra JM. Eertink JJ, et al. Among authors: lugtenburg pj. Blood Adv. 2023 Jan 24;7(2):214-223. doi: 10.1182/bloodadvances.2022008629. Blood Adv. 2023. PMID: 36306337 Free PMC article.
Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities.
Spanjaart AM, Pennings ERA, Kos M, Mutsaers PGNJ, Lugtenburg PJ, van Meerten T, van Doesum JA, Minnema MC, Jak M, van Dorp S, Vermaat JSP, van der Poel MWM, van Oijen MGH, Kuipers MT, Nijhof IS, Kersten MJ. Spanjaart AM, et al. Among authors: lugtenburg pj. JCO Oncol Pract. 2023 Mar;19(3):e407-e416. doi: 10.1200/OP.22.00501. Epub 2022 Dec 12. JCO Oncol Pract. 2023. PMID: 36508702 Free PMC article.
An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients.
Ferrández MC, Golla SSV, Eertink JJ, de Vries BM, Lugtenburg PJ, Wiegers SE, Zwezerijnen GJC, Pieplenbosch S, Kurch L, Hüttmann A, Hanoun C, Dührsen U, de Vet HCW; PETRA; Zijlstra JM, Boellaard R. Ferrández MC, et al. Among authors: lugtenburg pj. Sci Rep. 2023 Aug 12;13(1):13111. doi: 10.1038/s41598-023-40218-1. Sci Rep. 2023. PMID: 37573446 Free PMC article.
The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands.
Spanjaart AM, Pennings ERA, Mutsaers PGNJ, van Dorp S, Jak M, van Doesum JA, de Boer JW, Niezink AGH, Kos M, Vermaat JSP, Sijs-Szabo A, van der Poel MWM, Nijhof IS, Kuipers MT, Chamuleau MED, Lugtenburg PJ, Doorduijn JK, Serroukh YIM, Minnema MC, van Meerten T, Kersten MJ; Dutch CAR-T Tumorboard Consortium. Spanjaart AM, et al. Among authors: lugtenburg pj. Cancers (Basel). 2023 Aug 30;15(17):4334. doi: 10.3390/cancers15174334. Cancers (Basel). 2023. PMID: 37686611 Free PMC article.
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ. Thieblemont C, et al. Among authors: lugtenburg pj. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22. J Clin Oncol. 2023. PMID: 36548927 Free PMC article. Clinical Trial.
No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study.
Geerdes EE, Durmaz M, Lugtenburg PJ, Chamuleau MED, Visser O, Issa DE, Brouwer RE, Posthuma EFM, Zijlstra JM, Kersten MJ, Dinmohamed AG. Geerdes EE, et al. Among authors: lugtenburg pj. Blood Adv. 2023 Sep 12;7(17):4869-4873. doi: 10.1182/bloodadvances.2023010480. Blood Adv. 2023. PMID: 37389820 Free PMC article. No abstract available.
137 results